Heikal Shimaa A, Khedr Eman M, Othman Mai, Elsheikh Nesma G, Tawfik Heba M, Hassanin Hany I, Al-Shehaby Nouran, Eltaher Ashraf, Shamma Samir, Mohamed Ahmed S, Saber Mostafa, Lomomba Abdullah A, Ali Esraa, Safwat Shady M, Elfetoh Noha Abo, Fawi Gharib, Yousri Noha A, Salama Mohamed
Institute of Global Health and Human Ecology The American University in Cairo Cairo Egypt.
Neuropsychiatry Department Assiut University Assiut Egypt.
Alzheimers Dement (Amst). 2025 Aug 24;17(3):e70172. doi: 10.1002/dad2.70172. eCollection 2025 Jul-Sep.
Dementia, including Alzheimer's disease (AD), is a growing concern in Egypt, yet biomarker research in this population is scarce. Identifying serum biomarkers is essential for early diagnosis and understanding disease mechanisms in underrepresented groups.
We performed serum proteomic profiling on 20 Egyptian dementia patients and 10 cognitively unimpaired controls from the Egyptian Dementia Registry using mass spectrometry. Differential protein expression and pathway enrichment analyses were conducted.
Of 260 quantified proteins, 21 were significantly different between dementia patients and controls ( < 0.05). Several serine protease inhibitor and immunoglobulin family proteins were downregulated, while apolipoprotein A-II was upregulated in dementia. Enrichment analysis revealed associations with inflammation, complement activation, and lipid metabolism pathways.
This is the first serum proteomic study of dementia in an Egyptian cohort, highlighting coordinated changes in protein families involved in inflammation and lipid metabolism, and emphasizing the importance of biomarker research in diverse populations.
The study presents initial proteomic data from the Egyptian Dementia Registry.The Egyptian population has been underrepresented in the area of dementia research.Serine protease inhibitor G1, apolipoprotein A-II, and lipopolysaccharide binding protein emerged as significant proteins.The work lays the foundation for more understanding of molecular determinants in dementia in the Middle East.
包括阿尔茨海默病(AD)在内的痴呆症在埃及日益受到关注,但该人群的生物标志物研究却很匮乏。识别血清生物标志物对于在代表性不足的群体中进行早期诊断和了解疾病机制至关重要。
我们使用质谱法对来自埃及痴呆症登记处的20名埃及痴呆症患者和10名认知未受损的对照者进行了血清蛋白质组分析。进行了差异蛋白表达和通路富集分析。
在260种定量蛋白质中,痴呆症患者和对照者之间有21种存在显著差异(<0.05)。几种丝氨酸蛋白酶抑制剂和免疫球蛋白家族蛋白下调,而载脂蛋白A-II在痴呆症患者中上调。富集分析揭示了与炎症、补体激活和脂质代谢通路的关联。
这是埃及队列中首次进行的痴呆症血清蛋白质组研究,突出了参与炎症和脂质代谢的蛋白质家族的协同变化,并强调了在不同人群中进行生物标志物研究的重要性。
该研究展示了来自埃及痴呆症登记处的初步蛋白质组学数据。埃及人群在痴呆症研究领域的代表性不足。丝氨酸蛋白酶抑制剂G1、载脂蛋白A-II和脂多糖结合蛋白成为重要蛋白质。这项工作为更深入了解中东地区痴呆症的分子决定因素奠定了基础。